权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of the cardiac/vasculor hypertrophy and cardio-protection

心脏/血管肥大和心脏保护的机制

基本信息

批准号：
08670748
负责人：
KOHZUKI Masahiro
金额：
$ 1.41万
依托单位：
Tohoku University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1996
资助国家：
日本
起止时间：
1996 至 1997
项目状态：
已结题

项目摘要

1) Angiotensin converting enzyme (ACE) increased markedly in the infarct area and modetately in hypertrophied myocardium without changing the affinity compared to the sham-operated rats. The study confirms that cardiac ACE may participate in the pathophysiology of cardiac hypertrophy in chronic heart failure.2) We investigated the actions of f-Met-Leu-Phe (FMLP) and its cellular mechamism in human coronary arteries. A reverse transcription-polymerase chain reaction (RT-PCR) showed predominent expression of FMLP receptor homologues, FPRH1 and FPRH2 mRNA,in human coronary medial tissue relative to that in leukocytes.3) We assessed the renal-protective effect of long-acting antihypertensive drugs (losartan 5 mg/kg/day p.o., imidapril 5 mg/kg/day p.o., amlodipine 5 mg/kg/day p.o. ; in drinking solution for 12 weeks) in rats with chronic renal failure. The results indicate that these long-acting antihypertensive drugs equally have potency to protrct heart and kidney in rats with CRF.They also indicate that the kallikrein-kinin system might not play a major role in the cardio-and reno-protective effects of ACE inhibitors in rats with CRF.4) Chronic administration of a specific endothelin subtype A receptor antagonist, FR139317 (32 mg/kg/day i.p.) and an angiotensin converting enzyme inhibitor, enalapril (2mg/kg/day i.p.), in combination with moderate exercise were investigated in rats with chronic renal failure. Moderate exercise may protect renal function in this model. They also suggest that FR139317 may not have an additional antihypertensive and renal protective effect in this exercise model.

1) 与假手术组大鼠相比，梗死区血管紧张素转换酶（ACE）显着升高，肥厚心肌中血管紧张素转换酶（ACE）适度升高，而亲和力没有改变。该研究证实心脏ACE可能参与慢性心力衰竭心肌肥厚的病理生理学过程。2)我们研究了f-Met-Leu-Phe (FMLP)在人冠状动脉中的作用及其细胞机制。逆转录聚合酶链反应 (RT-PCR) 显示，相对于白细胞，人冠状动脉中层组织中 FMLP 受体同源物 FPRH1 和 FPRH2 mRNA 的表达较多。3) 我们评估了长效抗高血压药物（氯沙坦 5 mg/kg/天，口服、咪达普利 5）的肾脏保护作用。 mg/kg/天，口服，氨氯地平 5 mg/kg/天，口服;在患有慢性肾功能衰竭的大鼠中在饮用溶液中持续12周）。结果表明，这些长效抗高血压药物对 CRF 大鼠的心脏和肾脏同样具有保护作用。它们还表明，激肽释放酶-激肽系统可能不会在 ACE 抑制剂对 CRF 大鼠的心脏和肾脏保护作用中发挥主要作用。4) 长期服用特定的内皮素 A 亚型受体拮抗剂 FR139317 (32) mg/kg/天，腹腔注射）和血管紧张素转换酶抑制剂依那普利（2mg/kg/天，腹腔注射）与适度运动相结合，在慢性肾功能衰竭大鼠中进行了研究。在此模型中，适度运动可以保护肾功能。他们还表明，FR139317 在此运动模型中可能没有额外的抗高血压和肾脏保护作用。